Postprandial insulin Secretion Determines the Progressive Nature of Type-2 Diabe

With increasing duration of type 2 diabetes it was found that decreases in postprandial insulin secretion are more pronounced. Type-2 diabetes is a progressive disease. However, little is known about whether decreased fasting or postprandial pancreatic ß-cell responsiveness is more prominent with increased duration of diabetes. The aim of this study was to evaluate the relationship between insulin secretion both during fasting and 2 h postprandial, and the duration of diabetes in type-2 diabetic patients.

We conducted a meal tolerance test in 1466 type-2 diabetic patients and calculated fasting (M0) and postprandial (M1) ß-cell responsiveness.

Results showed that the fasting C-peptide, postprandial C-peptide, values were lower, but HbA1c values were higher, in patients with diabetes duration > 10 years than those in other groups. There was no difference in the HbA1c levels according to the tertiles of their fasting C-peptide level. However, in a group of patients with highest postprandial C-peptide tertile, the HbA1c values were significantly lower than those in other groups. After adjustment of age, sex, and body mass index (BMI), the duration of diabetes was found to be negatively correlated with fasting C-peptide, postprandial C-peptide respectively.

From the results it was concluded that with increasing duration of diabetes, the decrease of postprandial insulin secretion is becoming more prominent, and postprandial ß-cell responsiveness may be a more important determinant for glycemic control than fasting ß-cell responsiveness.

European Journal of Endocrinology, Vol 155, Issue 4, 615-622

================================

Start your own walking program
New StepTracker Available at special prices. See the results of the Step Program Study.
https://www.diabetesincontrol.com/programs/steps/index.shtml
Purchase your own pedometers and receive the Steps to Health Program at no charge. https://www.rx4betterhealth.com/steptracker/
The Only Pedometer on the Market That Comes With a Program for Success!

=========================

DID YOU KNOW:
FDA Approves New Label for Vytorin: Slight edge goes to Vytorin over Crestor in lowering LDL. This study, now included in the label for VYTORIN, of 2,959 patients with high cholesterol not at their LDL cholesterol goal showed that VYTORIN, along with diet when diet alone is not enough, lowered LDL "bad" cholesterol more than Crestor across all study dose comparisons, 52-61 percent for VYTORIN 10/20 mg to 10/80 mg, and 46-57 percent for Crestor 10 mg to 40 mg.
VYTORIN, which contains ezetimibe and simvastatin, is the only product approved to treat the two sources of cholesterol by inhibiting the production of cholesterol in the liver and blocking the absorption of cholesterol in the intestine, including cholesterol from food.